The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells
PLOS ONE · 08.02.2023 · 18 (2) · e0280741
DOI: 10.1371/journal.pone.0280741 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.02.2023. Verfasst von Ewelina Woźniak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic Agents, Atherosclerosis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Medyczny w Lodzi.
Abstract (Originalsprache)
Atherosclerosis and cardiovascular events can be prevented, or treated, using statin therapy, either alone or in combination with ezetimibe. Chronic inflammation, vascular proliferation, and the development of atherosclerosis are also influenced by 25-hydroxycholesterol (25-OHC). The aim of the study was to compare the direct pleiotropic effects of two commonly-used statins (atorvastatin, rosuvastatin), ezetimibe, and their combinations, on the mRNA expression of pro-inflammatory IL1β , IL-18 and IL-23 and anti-inflammatory TGFβ , IL-35 ( EBI3 , IL-12 subunits), IL-10 and IL-37 , in endothelial cells damaged by 25-OHC. It also analyzed IL-35 expression at the protein level. HUVECs were stimulated with atorvastatin (5 μM), rosuvastatin (10 μM), ezetimibe (1.22 μM), atorvastatin-ezetimibe (5 μM + 1.22 μM) or rosuvastatin-ezetimibe (10 μM + 1.22 μM), with or without pre-incubation with 10 μg/mL 25-OHC. mRNA expression was analyzed by real-time PCR. The protein level of IL-35 was analyzed by ELISA. In the pre-stimulated HUVECs, atorvastatin and rosuvastatin decreased mRNA expression of IL1β , IL-18 , IL-23 , TGFβ , IL35 and increased mRNA expression of IL-10 and IL-37 compared to 25-OHC. Furthermore, only incubation with rosuvastatin and rosuvastatin-ezetimibe decreased IL-35 mRNA and protein levels. Ezetimibe down-regulated only IL1β . Treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe reversed the effect of 25-OHC in IL1β , IL-18 and IL-35 mRNA expression. In conclusion, rosuvastatin has the strongest anti-inflammatory effects and is the best at reducing the effect of oxysterols. Both statins exert a greater anti-inflammatory effect than ezetimibe. The anti-inflammatory effect of the combination therapies appears to be based on the effects of the statins alone and not their combination with ezetimibe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Diseases and Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Lodz, Poland.
ORCID-Profile: Ewelina Woźniak
Förderung
- Uniwersytet Medyczny w Lodzi
Zitieren
APA
Woźniak, E., Broncel, M., Niedzielski, M., Woźniak, A., & Gorzelak-Pabiś, P. (2023). The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PLOS ONE, 18(2), e0280741. https://doi.org/10.1371/journal.pone.0280741
Vancouver
Woźniak E, Broncel M, Niedzielski M, Woźniak A, Gorzelak-Pabiś P. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PLOS ONE. 2023;18(2):e0280741. doi:10.1371/journal.pone.0280741
BibTeX
@article{Woniak2023,
author = {Woźniak, Ewelina and Broncel, Marlena and Niedzielski, Mateusz and Woźniak, Agnieszka and Gorzelak-Pabiś, Paulina},
title = {The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {2},
pages = {e0280741},
doi = {10.1371/journal.pone.0280741}
}
EUVIMED